Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors

European Journal of Medicinal Chemistry

Volumn 89, Issue , 2015, Pages 581-596

  Yang, Weimin ^a   Chen, Yadong ^a   Zhou, Xiang ^a   Gu, Yazhou ^a   Qian, Wenqi ^a   Zhang, Fan ^a   Han, Wei ^a   Lu, Tao ^a   Tang, Weifang ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Antitumor agents; B Raf inhibitors; DFG Out; Melanoma

Indexed keywords

2 AMINO 3 PURINYLPYRIDINE; 3 [(3 (9H PURIN 6 YL)PYRIDIN 2 YL)AMINO] 4 METHYL N [3 (TRIFLUOROMETHYL)PHENYL]BENZAMIDE; 3 [(3 (9H PURIN 6 YL)PYRIDIN 2 YL)AMINO] N (3 BROMO 4 CHLOROPHENYL) 4 METHYLBENZAMIDE; 3 [(3 (9H PURIN 6 YL)PYRIDIN 2 YL)AMINO] N (3 CHLOROPHENYL) 4 METHYLBENZAMIDE; 3 [(3 (9H PURIN 6 YL)PYRIDIN 2 YL)AMINO] N (4 CHOLORO 3 METHYLPHENYL) 4 METHYLBENZAMIDE; 3 [(3 (9H PURIN 6 YL)PYRIDIN 2 YL)AMINO] N [3 (CYANOPHENYL) 4 METHYLBENZAMIDE; 3 [(3 (9H PURIN 6 YL)PYRIDIN 2 YL)AMINO] N [3 (FLUOROPHENYL) 4 METHYLBENZAMIDE; 3 [(3 (9H PURIN 6 YL)PYRIDIN 2 YL)AMINO] N [3 (ISOPROPHENYL) 4 METHYLBENZAMIDE; ANTINEOPLASTIC AGENT; B RAF KINASE INHIBITOR; SORAFENIB; UNCLASSIFIED DRUG; VEMURAFENIB; 3-((3-(9H-PURIN-6-YL)PYRIDIN-2-YL)AMINO)-N-(4-CHLORO-3-METHYLPHENYL)-4-METHYLBENZAMIDE; AMIDE; B RAF KINASE; BENZAMIDE DERIVATIVE; PROTEIN KINASE INHIBITOR; PURINE DERIVATIVE; UREA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL ACTIVITY; CANCER CELL CULTURE; DRUG EFFICACY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC50; MELANOMA; MOUSE; NONHUMAN; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG DESIGN; DRUG EFFECTS; DRUG SCREENING; FEMALE; METABOLISM; NEOPLASMS, EXPERIMENTAL; NUDE MOUSE; PATHOLOGY; STRUCTURE ACTIVITY RELATION; SYNTHESIS; TUMOR CELL LINE;

AMIDES; ANIMALS; BENZAMIDES; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR STRUCTURE; NEOPLASMS, EXPERIMENTAL; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PURINES; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

EID: 84908510103     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.10.039     Document Type: Article

References (24)

1. C. Peyssonnaux A. Eychene The Raf/MEK/ERK pathway: new concepts of activation Biol. Cell 93 2001 53 62
2. H.F. Li Y.D. Chen S.S. Rao X.M. Chen H.C. Liu J.H. Qin W.F. Tang Y. Wang X.F. Zhou T. Lu Recent advances in the research and development of B-Raf inhibitors Curr. Med. Chem. 17 2010 1618 1634
3. P.T.C. Wan M.J. Garnett S.M. Roe S. Lee D. Niculescu-Duvaz V.M. Good C.M. Jones C.J. Marshall C.J. Springer D. Barford R. Marais Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 116 2004 855 867
4. J. Cohen M.Z. Xing E. Mambo Z.M. Guo G.G. Wu B. Trink U. Beller W.H. Westra P.W. Ladenson D. Sidransky BRAF mutation in papillary thyroid carcinoma J. Natl. Cancer Inst. 95 2003 625 627
5. C. Sawyers Targeted cancer therapy Nature 432 2004 294 297
6. H.B. El-Nassan Recent progress in the identification of BRAF inhibitors as anti-cancer agents Eur. J. Med. Chem. 72 2014 170 205
7. W.M. Yang Y.D. Chen Y.M. Zhang S.Z. Tang H.L. Chen W.F. Tang T. Lu Design, synthesis and antitumor activities of bis-arylureas and bis-arylamides based on 1H-benzo[d]imidazole moiety as novel b-Raf(V600E)/VEGFR2 dual inhibitors Lett. Drug Des. Discov. 11 2014 1079 1089
8. P.B. Chapman A. Hauschild C. Robert J.B. Haanen P. Ascierto J. Larkin R. Dummer C. Garbe A. Testori M. Maio D. Hogg P. Lorigan C. Lebbe T. Jouary D. Schadendorf A. Ribas S.J. O'Day J.A. Sosman J.M. Kirkwood A.M.M. Eggermont B. Dreno K. Nolop J. Li B. Nelson J. Hou R.J. Lee K.T. Flaherty G.A. McArthur Improved survival with Vemurafenib in melanoma with BRAFV600E mutation N. Engl. J. Med. 364 2011 2507 2516
9. A. Hauschild J.J. Grob L.V. Demidov T. Jouary R. Gutzmer M. Millward P. Rutkowski C.U. Blank W.H. Miller E. Kaempgen S. Martin-Algarra B. Karaszewska C. Mauch V. Chiarion-Sileni A.M. Martin S. Swann P. Haney B. Mirakhur M.E. Guckert V. Goodman P.B. Chapman Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Lancet 380 2012 358 365
10. K.T. Flaherty I. Puzanov K.B. Kim A. Ribas G.A. McArthur J.A. Sosman P.J. O'Dwyer R.J. Lee J.F. Grippo K. Nolop P.B. Chapman Inhibition of mutated, activated BRAF in metastatic melanoma N. Engl. J. Med. 363 2010 809 819
11. R.M. Anforth T.C.M.P. Blumetti R.F. Kefford R. Sharma R.A. Scolyer S. Kossard G.V. Long P. Fernandez-Penas Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma Brit. J. Dermatol. 167 2012 1153 1160
12. G.S. Falchook G.V. Long R. Kurzrock K.B. Kim T.H. Arkenau M.P. Brown O. Hamid J.R. Infante M. Millward A.C. Pavlick S.J. O'Day S.C. Blackman C.M. Curtis P. Lebowitz B. Ma D. Ouellet R.F. Kefford Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial Lancet 379 2012 1893 1901
13. P.I. Poulikakos C. Zhang G. Bollag K.M. Shokat N. Rosen RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF Nature 464 2010 427 430
14. F. Su A. Viros C. Milagre K. Trunzer G. Bollag O. Spleiss J.S. Reis X.J. Kong R.C. Koya K.T. Flaherty P.B. Chapman M.J. Kim R. Hayward M. Martin H. Yang Q.Q. Wang H. Hilton J.S. Hang J. Noe M. Lambros F. Geyer N. Dhomen I. Niculescu-Duvaz A. Zambon D. Niculescu-Duvaz N. Preece L. Robert N.J. Otte S. Mok D. Kee Y. Ma C. Zhang G. Habets E.A. Burton B. Wong H. Nguyen M. Kockx L. Andries B. Lestini K.B. Nolop R.J. Lee A.K. Joe J.L. Troy R. Gonzalez T.E. Hutson I. Puzanov B. Chmielowski C.J. Springer G.A. McArthur J.A. Sosman R.S. Lo A. Ribas R. Marais RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors N. Engl. J. Med. 366 2012 207 215
15. M. Okaniwa M. Hirose T. Arita M. Yabuki A. Nakamura T. Takagi T. Kawamoto N. Uchiyama A. Sumita S. Tsutsumi T. Tottori Y. Inui B.C. Sang J. Yano K. Aertgeerts S. Yoshida T. Ishikawa Discovery of a selective kinase inhibitor (TAK-632) targeting pan-RAF inhibition: design, synthesis, and biological evaluation of C-7-substituted 1,3-benzothiazole derivatives J. Med. Chem. 56 2013 6478 6494
16. E.K. Shim, N.D. Kim, T.B. Shim, S.Y. Kim, Novel purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against raf kinase, containing same as active ingredient, PCT Int. Appl., WO2012074249 A2 (2012) 81.
17. W.K. Choi M.I. El-Gamal H.S. Choi D. Baek C.H. Oh New diarylureas and diarylamides containing 1,3,4-triarylpyrazole scaffold: synthesis, antiproliferative evaluation against melanoma cell lines, ERK kinase inhibition, and molecular docking studies Eur. J. Med. Chem. 46 2011 5754 5762
18. A. Gopalsamy G. Ciszewski Y. Hu F. Lee L. Feldberg E. Frommer S. Kim K. Collins D. Wojciechowicz R. Mallon Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors Bioorg. Med. Chem. Lett. 19 2009 2735 2738
19. J. Tang K.E. Lackey S.H. Dickerson The discovery of potent and selective 4-aminothienopyridines as B-Raf kinase inhibitors Bioorg. Med. Chem. Lett. 23 2013 66 70
20. J. Dietrich V. Gokhale X. Wang L.H. Hurley G.A. Flynn Application of a novel [3+2] cycloaddition reaction to prepare substituted imidazoles and their use in the design of potent DFG-out allosteric B-Raf inhibitors Bioorg. Med. Chem. 18 2010 292 304
21. R.K. Robins E.F. Godefroi E.C. Taylor L.R. Lewis A. Jackson Purine nucleosides. I. The synthesis of certain 6-substituted-9-(tetrahydro-2-pyrany1)-purines as models of purine deoxynucleosides J. Am. Chem. Soc. 83 1961 2574 2579
22. J.B. Press R. Falotico Z.G. Hajos R.A. Sawyers R.M. Kanojia L. Williams B. Haertlein J.A. Kauffman C. Lakas-Weiss J.J. Salata Synthesis and SAR of 6-substituted purine derivatives as novel selective positive inotropes J. Med. Chem. 35 1992 4509 4515
23. M.M. Vasbinder B. Aquila M. Augustin H. Chen T. Cheung D. Cook L. Drew B.P. Fauber S. Glossop M. Grondine E. Hennessy J. Johannes S. Lee P. Lyne M. Mortl C. Omer S. Palakurthi T. Pontz J. Read L. Sha M. Shen S. Steinbacher H. Wang A. Wu M. Ye Discovery and optimization of a novel series of potent mutant B-Raf(V600E) selective kinase inhibitors J. Med. Chem. 56 2013 1996 2015
24. S.M. Soond P.A. Townsend S.P. Barry R.A. Knight D.S. Latchman A. Stephanou ERK and the F-box protein betaTRCP target STAT1 for degradation J. Biol. Chem. 283 2008 16077 16083